Abbisko Therapeutics

Executive Summary

Abbisko Therapeutics is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing innovative small molecule therapies for oncology and other major diseases. The company's deep expertise in oncology biology and translational medicine has enabled a pipeline focused on key oncogenic pathways and the tumor microenvironment. Its lead asset, pimicotinib (ABSK-021), is a highly selective CSF-1R inhibitor currently in Phase 2/3 trials for tenosynovial giant cell tumor (TGCT) and Phase 2 studies for other indications including advanced solid tumors and chronic graft-versus-host disease. Abbisko went public on the Hong Kong Stock Exchange in 2021 and has established partnerships with global biopharma companies to advance its pipeline. The company's differentiated approach and robust preclinical data position it as a potential leader in targeted oncology therapies in China and globally.

Upcoming Catalysts (preview)

• Q3 2026Topline Phase 2 data for pimicotinib in TGCT75% success
• Q1 2027Initiation of Phase 3 registrational trial for pimicotinib in TGCT85% success
• TBDPotential partnership or licensing deal for pimicotinib outside China60% success